Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0686 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| MK0686 | DRUG | - |
Inclusion Criteria: * Patients with a clinical and radiographic diagnosis of osteoarthritis of the hip or knee,either prior NSAID or Acetaminophen users within the ARA functional class I,II or III and with no clinically significant diseases * Patients required to demonstrate a flare of the signs an...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
MK0686 is an investigational small molecule being studied for osteoarthritis and postoperative pain. Merck & Company, Inc. has evaluated it in Phase 2 clinical trials in patients with osteoarthritis and in patients with postsurgery dental pain. It has not been approved for any indication and remains in clinical development.
MK0686 targets BDKRB1, also known as the bradykinin B1 receptor. It acts as an antagonist at this receptor. The bradykinin B1 receptor is associated with pain signaling and inflammatory responses, which is the rationale for studying MK0686 in osteoarthritis and postoperative pain.
MK0686 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck sponsored the Phase 2 clinical trials of MK0686 in osteoarthritis and in postsurgery dental pain.
MK0686 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. Both of its recorded Phase 2 trials have been completed, and no trials are currently listed as active.
MK0686 has been studied in two completed Phase 2 trials. NCT00533403 evaluated MK0686 in postsurgery dental pain with 114 participants. NCT00296569 assessed the safety and efficacy of MK0686 in patients with osteoarthritis with 150 participants. Both were randomized, double-blind studies.
Yes, MK0686 and MK-686 refer to the same investigational compound from Merck. The Phase 2 osteoarthritis trial is titled using the MK-686 spelling, while the postsurgery dental pain trial uses MK0686. Both names identify the same bradykinin B1 receptor antagonist.